Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Faissner

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Journal of Neurology|May 28, 2022
Resurrection of sildenafil: potential for Huntington's Disease, too?Jannis Achenbach, Simon Faissner, Carsten Saft
Frontiers in Immunology|June 7, 2022
Contemplating Dichotomous Nature of Gamma Delta T Cells for ImmunotherapyJaydeep Bhat, Katarzyna Placek, Simon Faissner
Brain Sciences|April 3, 2021
Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World CohortJannis Achenbach, Carsten Saft, Simon Faissner
Therapeutic Advances in Neurological Disorders|July 28, 2022
Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohortJannis Achenbach, Carsten Saft, Simon Faissner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 24, 2019
Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapyBjörn Ambrosius, Ralf Gold, Andrew Chan, et al.
Annals of Clinical and Translational Neurology|January 12, 2026
Effects of Biological Sex and Age on Cerebrospinal Fluid Markers-A Retrospective Observational StudyIsabel-Sophie Hafer, Simon Faissner, Ralf Gold, et al.
Nature Reviews. Drug Discovery|August 11, 2019
Progressive multiple sclerosis: from pathophysiology to therapeutic strategiesSimon Faissner, Jason R Plemel, Ralf Gold, et al.
Journal of Central Nervous System Disease|May 24, 2014
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosisRobert Hoepner, Simon Faissner, Anke Salmen, et al.
Frontiers in Immunology|June 17, 2026
Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease - case reportGregor Hütter, Maximilian Winkelhausen, Lars Tönges, et al.
Journal of the Neurological Sciences|August 20, 2016
"Punched nerve syndrome" as contributing factor for "Saturday night palsy"Simon Faissner, Carsten Lukas, Andrew Chan, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Journal of Neurology|May 28, 2022
Resurrection of sildenafil: potential for Huntington's Disease, too?Jannis Achenbach, Simon Faissner, Carsten Saft
Frontiers in Immunology|June 7, 2022
Contemplating Dichotomous Nature of Gamma Delta T Cells for ImmunotherapyJaydeep Bhat, Katarzyna Placek, Simon Faissner
Brain Sciences|April 3, 2021
Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World CohortJannis Achenbach, Carsten Saft, Simon Faissner
Therapeutic Advances in Neurological Disorders|July 28, 2022
Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohortJannis Achenbach, Carsten Saft, Simon Faissner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 24, 2019
Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapyBjörn Ambrosius, Ralf Gold, Andrew Chan, et al.
Annals of Clinical and Translational Neurology|January 12, 2026
Effects of Biological Sex and Age on Cerebrospinal Fluid Markers-A Retrospective Observational StudyIsabel-Sophie Hafer, Simon Faissner, Ralf Gold, et al.
Nature Reviews. Drug Discovery|August 11, 2019
Progressive multiple sclerosis: from pathophysiology to therapeutic strategiesSimon Faissner, Jason R Plemel, Ralf Gold, et al.
Journal of Central Nervous System Disease|May 24, 2014
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosisRobert Hoepner, Simon Faissner, Anke Salmen, et al.
Frontiers in Immunology|June 17, 2026
Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease - case reportGregor Hütter, Maximilian Winkelhausen, Lars Tönges, et al.
Journal of the Neurological Sciences|August 20, 2016
"Punched nerve syndrome" as contributing factor for "Saturday night palsy"Simon Faissner, Carsten Lukas, Andrew Chan, et al.
Pageof 9